Vitrolife is forecast to grow earnings and revenue by 103.8% and 6.6% per annum respectively. EPS is expected to grow by 103.8% per annum. Return on equity is forecast to be 7.2% in 3 years.
Key information
103.8%
Earnings growth rate
103.78%
EPS growth rate
Biotechs earnings growth
16.7%
Revenue growth rate
6.6%
Future return on equity
7.23%
Analyst coverage
Low
Last updated
30 Jun 2026
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
BATS-CHIXE:VITRS - Analysts future estimates and past financials data (SEK Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
4,055
703
784
1,040
5
12/31/2027
3,776
600
709
948
5
12/31/2026
3,501
480
609
832
5
3/31/2026
3,405
-5,011
486
738
N/A
12/31/2025
3,440
-5,012
388
635
N/A
9/30/2025
3,507
440
468
742
N/A
6/30/2025
3,541
455
429
693
N/A
3/31/2025
3,610
498
575
778
N/A
12/31/2024
3,609
513
705
907
N/A
9/30/2024
3,555
-3,805
649
811
N/A
6/30/2024
3,535
-3,799
671
819
N/A
3/31/2024
3,499
-3,836
655
795
N/A
12/31/2023
3,512
-3,851
638
757
N/A
9/30/2023
3,462
402
650
752
N/A
6/30/2023
3,412
388
652
738
N/A
3/31/2023
3,336
412
631
706
N/A
12/31/2022
3,234
394
549
636
N/A
9/30/2022
2,893
353
366
470
N/A
6/30/2022
2,501
349
288
377
N/A
3/31/2022
2,054
305
249
331
N/A
12/31/2021
1,681
341
321
384
N/A
9/30/2021
1,549
415
525
555
N/A
6/30/2021
1,464
399
515
545
N/A
3/31/2021
1,291
325
455
479
N/A
12/31/2020
1,246
287
336
356
N/A
9/30/2020
1,273
276
278
303
N/A
6/30/2020
1,331
294
332
361
N/A
3/31/2020
1,502
377
315
399
N/A
12/31/2019
1,480
383
N/A
413
N/A
9/30/2019
1,391
371
N/A
412
N/A
6/30/2019
1,297
339
N/A
344
N/A
3/31/2019
1,199
324
N/A
341
N/A
12/31/2018
1,151
310
N/A
349
N/A
9/30/2018
1,102
294
N/A
343
N/A
6/30/2018
1,064
284
N/A
341
N/A
3/31/2018
1,066
276
N/A
321
N/A
12/31/2017
1,046
264
N/A
312
N/A
9/30/2017
1,026
255
N/A
281
N/A
6/30/2017
991
234
N/A
243
N/A
3/31/2017
913
211
N/A
204
N/A
12/31/2016
856
190
N/A
181
N/A
9/30/2016
804
188
N/A
197
N/A
6/30/2016
771
196
N/A
210
N/A
3/31/2016
747
186
N/A
196
N/A
12/31/2015
722
183
N/A
194
N/A
9/30/2015
660
154
N/A
138
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VITRS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.4%).
Earnings vs Market: VITRS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: VITRS is expected to become profitable in the next 3 years.
Revenue vs Market: VITRS's revenue (6.6% per year) is forecast to grow faster than the UK market (4.7% per year).
High Growth Revenue: VITRS's revenue (6.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VITRS's Return on Equity is forecast to be low in 3 years time (7.2%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/05 15:53
End of Day Share Price
2026/05/18 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vitrolife AB (publ) is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.